About The Study: In this study, semaglutide was associated with reduced opioid overdose risk in patients with comorbid type 2 diabetes and opioid use disorder, suggesting its potential therapeutic value for preventing overdoses. The results need validation from other data resources and study populations. Further research is warranted to investigate the underlying mechanisms and randomized clinical trials are necessary to corroborate the clinical effects on opioid use disorder.
Corresponding Authors: To contact the corresponding authors, email Rong Xu, PhD, ( rxx@case.edu ) and Nora D. Volkow, MD, ( nvolkow@nida.nih.gov ).
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2024.35247)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.35247?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=092524
About JAMA Network Open : JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.
JAMA Network Open